Signals
Survodutide’s Phase III data raise a bigger question than weight loss
Phase III SYNCHRONIZE-2 data show that the investigational glucagon/GLP-1 dual agonist survodutide can reduce body weight and improve glycaemic control in people with obesity and type 2 diabetes
AI Improved Sepsis Compliance. Patients Still Need the Outcome Proof.
Cardiac rehab saves lives. Health systems still treat it like optional aftercare
BMI is not enough. Cardiometabolic risk is hiding in where fat lives
MS Has Learnt to Stop Inflammation. It Still Cannot Repair the Damage.
Resistant hypertension may need a diagnostic revolution, not just another drug
When diabetes tech fails, personalised care fails with it
For Drug-Resistant Epilepsy, Surgery Should Not Be the Only Door
Gonorrhoea Is Not Disappearing. Too Many Systems Are Failing to See It.
Heart pumps save lives. FDA’s latest Impella alerts show why cardiac device safety cannot stop at approval.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.